Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0192 | 0.2253 | 0.2253 |
Loa Loa (eye worm) | hypothetical protein | 0.0173 | 0.1882 | 0.1882 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0173 | 0.1882 | 0.1882 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0192 | 0.2253 | 0.5 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0173 | 0.1882 | 0.8351 |
Echinococcus multilocularis | Tolloid protein 1 | 0.0597 | 1 | 1 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0192 | 0.2253 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0243 | 0.3223 | 0.3223 |
Loa Loa (eye worm) | hypothetical protein | 0.0573 | 0.9535 | 0.9535 |
Brugia malayi | Fibulin-1 precursor | 0.0192 | 0.2253 | 1 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0597 | 1 | 1 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.0597 | 1 | 1 |
Loa Loa (eye worm) | AStacin protease | 0.0373 | 0.5714 | 0.5714 |
Onchocerca volvulus | Arrow homolog | 0.0173 | 0.1882 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0192 | 0.2253 | 0.2253 |
Loa Loa (eye worm) | hypothetical protein | 0.0173 | 0.1882 | 0.1882 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0192 | 0.2253 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 0 | The chronotropic effect tested in vitro by using isolated blood-perfused dog heart preparations | ChEMBL. | 1331445 |
Activity (functional) | = 4 | The inotropic effect tested in vitro by using isolated blood-perfused dog heart preparations | ChEMBL. | 1331445 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.